<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The compound 5-(4-chlorophenyl)-2,4-dihydro-4-ethyl-3H-1,2,4-triazol-3-one (MDL 27,192) was evaluated in a variety of <z:e sem="disease" ids="C1519106" disease_type="Experimental Model of Disease" abbrv="">rodent models</z:e> to assess its <z:chebi fb="0" ids="35623">anticonvulsant</z:chebi> profile and its potential neuroprotective activity </plain></SENT>
<SENT sid="1" pm="."><plain>MDL 27,192 demonstrated <z:chebi fb="0" ids="35623">anticonvulsant</z:chebi> activity in a wide range of <z:e sem="disease" ids="C0014544" disease_type="Disease or Syndrome" abbrv="">epilepsy</z:e> models that are genetically-based (audiogenic <z:hpo ids='HP_0001250'>seizures</z:hpo> in the <z:hpo ids='HP_0001250'>seizure</z:hpo> susceptible <z:chebi fb="28" ids="35299">DBA</z:chebi>/2J or Frings mouse; spike wave <z:hpo ids='HP_0001250'>seizures</z:hpo> in genetic <z:mp ids='MP_0003216'>absence epilepsy</z:mp> rats of Strasbourg (GAERS), electrically-based (<z:chebi fb="28" ids="39005,39010">MES</z:chebi> <z:hpo ids='HP_0001250'>seizures</z:hpo> in mice and rats, corneally-kindled <z:hpo ids='HP_0001250'>seizures</z:hpo> in rats) and chemically-based (<z:chebi fb="0" ids="3092">bicuculline</z:chebi>, PTZ, picrotoxin, <z:chebi fb="0" ids="44111">3-mercaptopropionic acid</z:chebi>, <z:chebi fb="0" ids="16675">quinolinic acid</z:chebi> and <z:chebi fb="23" ids="28973">strychnine</z:chebi>) </plain></SENT>
<SENT sid="2" pm="."><plain>When compared to valproate, orally administered MDL 27,192 was 17-48-fold more potent as an <z:chebi fb="0" ids="35623">anticonvulsant</z:chebi> and showed a safety index one to three-fold greater </plain></SENT>
<SENT sid="3" pm="."><plain>Following a timed intravenous administration of PTZ to mice, MDL 27,192, but not phenytoin or carbamazepine, consistently increased the latencies to first twitch and <z:hpo ids='HP_0002169'>clonus</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>MDL 27,192 was active in a genetic model of <z:mp ids='MP_0003216'>absence epilepsy</z:mp>, the GAERS rat model </plain></SENT>
<SENT sid="5" pm="."><plain>These data indicate that MDL 27,192 likely exerts its <z:chebi fb="0" ids="35623">anticonvulsant</z:chebi> action by affecting <z:hpo ids='HP_0001250'>seizure</z:hpo> spread and by raising <z:hpo ids='HP_0001250'>seizure</z:hpo> threshold </plain></SENT>
<SENT sid="6" pm="."><plain>MDL 27,192 did not display any signs of tolerance following subchronic (15 day) administration </plain></SENT>
<SENT sid="7" pm="."><plain>In tests of neuroprotective potential, MDL 27,192 reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> volume in a permanent middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> model of focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> in rats and reduced the loss of hippocampal dentate hilar neurons in an animal model of unilateral head injury </plain></SENT>
<SENT sid="8" pm="."><plain>In summary, MDL 27,192 possesses a broad-spectrum <z:chebi fb="0" ids="35623">anticonvulsant</z:chebi> profile </plain></SENT>
<SENT sid="9" pm="."><plain>The potential for reduced tolerance and neuroprotective activity are additional positive features of MDL 27,192's preclinical profile </plain></SENT>
</text></document>